These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 21889325)

  • 1. GOLD COPD stage I is not associated with increased risk of death.
    Quanjer PH; Furberg CD
    Respir Med; 2012 Jan; 106(1):153. PubMed ID: 21889325
    [No Abstract]   [Full Text] [Related]  

  • 2. A mixed methods study to compare models of spirometry delivery in primary care for patients at risk of COPD.
    Walters JA; Hansen EC; Johns DP; Blizzard EL; Walters EH; Wood-Baker R
    Thorax; 2008 May; 63(5):408-14. PubMed ID: 18024537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A unique spirometric phenotype in COPD.
    Bon JM; Weissfeld JL; Sciurba FC
    Am J Respir Crit Care Med; 2008 Aug; 178(4):431-2. PubMed ID: 18676963
    [No Abstract]   [Full Text] [Related]  

  • 4. Prognostic Value of the Six-Second Spirometry in Patients with Chronic Obstructive Pulmonary Disease: A Cohort Study.
    Prats E; Tejero E; Pardo P; Gavilán A; Galera R; Donado JR; Racionero MÁ; Casitas R; Zapatero A; García-Río F
    PLoS One; 2015; 10(10):e0140855. PubMed ID: 26489023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pilot study to monitor changes in spirometry and lung volume, following an exacerbation of Chronic Obstructive Pulmonary Disease (COPD), as part of a supported discharge program.
    Cushen B; McCormack N; Hennigan K; Sulaiman I; Costello RW; Deering B
    Respir Med; 2016 Oct; 119():55-62. PubMed ID: 27692148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is forced expiratory volume in six seconds a valid alternative to forced vital capacity?
    Vandevoorde J; Swanney M
    Eur Respir J; 2006 Dec; 28(6):1288-9; author reply 1289-90. PubMed ID: 17138690
    [No Abstract]   [Full Text] [Related]  

  • 7. Development and validation of a claims-based prediction model for COPD severity.
    Macaulay D; Sun SX; Sorg RA; Yan SY; De G; Wu EQ; Simonelli PF
    Respir Med; 2013 Oct; 107(10):1568-77. PubMed ID: 23806285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic obstructive pulmonary disease in heart failure: accurate diagnosis and treatment.
    Güder G; Brenner S; Störk S; Hoes A; Rutten FH
    Eur J Heart Fail; 2014 Dec; 16(12):1273-82. PubMed ID: 25345927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lower limit of normal or FEV1/FVC < 0.70 in diagnosing COPD: an evidence-based review.
    Mohamed Hoesein FA; Zanen P; Lammers JW
    Respir Med; 2011 Jun; 105(6):907-15. PubMed ID: 21295958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Usefulness of GOLD classification of COPD severity.
    Köhler D; Fischer J; Raschke F; Schönhofer B
    Thorax; 2003 Sep; 58(9):825. PubMed ID: 12947152
    [No Abstract]   [Full Text] [Related]  

  • 11. COPD, restrictive syndrome and inflammation.
    Fimognari FL; Moro L; Antonelli Incalzi R
    Thorax; 2005 Jul; 60(7):612-3; author reply 612-3. PubMed ID: 15994272
    [No Abstract]   [Full Text] [Related]  

  • 12. Spirometry in old age.
    Allen SC
    Age Ageing; 2003 Jan; 32(1):4-5. PubMed ID: 12540339
    [No Abstract]   [Full Text] [Related]  

  • 13. Lung function impairment, COPD hospitalisations and subsequent mortality.
    Garcia-Aymerich J; Serra Pons I; Mannino DM; Maas AK; Miller DP; Davis KJ
    Thorax; 2011 Jul; 66(7):585-90. PubMed ID: 21515553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Shifting the goalpost to stay younger: normal spirometry but short of breath!
    Bhatt SP
    Chest; 2007 Jun; 131(6):1990; author reply 1990. PubMed ID: 17565039
    [No Abstract]   [Full Text] [Related]  

  • 15. Prevalence and diagnosis of chronic obstructive pulmonary disease among smokers at risk. A comparative study of case-finding vs. screening strategies.
    Sansores RH; Ramírez-Venegas A; Hernández-Zenteno R; Mayar-Maya ME; Pérez-Bautista OG; Velázquez Uncal M
    Respir Med; 2013 Apr; 107(4):580-6. PubMed ID: 23313037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What evidence could validate the definition of COPD?
    de Marco R
    Thorax; 2008 Sep; 63(9):756-7. PubMed ID: 18728199
    [No Abstract]   [Full Text] [Related]  

  • 17. Predicting inadequate spirometry technique and the use of FEV1/FEV3 as an alternative to FEV1/FVC for patients with mild cognitive impairment.
    Allen S; Yeung P; Janczewski M; Siddique N
    Clin Respir J; 2008 Oct; 2(4):208-13. PubMed ID: 20298336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting development and progression of COPD.
    Quanjer PH; Steenbruggen I; Ruppel G; Swanney MP
    Thorax; 2008 Nov; 63(11):1027-8; author reply 1028. PubMed ID: 18984822
    [No Abstract]   [Full Text] [Related]  

  • 19. Point: Is an increase in FEV₁ and/or FVC ≥ 12% of control and ≥ 200 mL the best way to assess positive bronchodilator response? Yes.
    Pellegrino R; Brusasco V
    Chest; 2014 Sep; 146(3):536-537. PubMed ID: 25180717
    [No Abstract]   [Full Text] [Related]  

  • 20. The forgotten message from gold: FVC is a primary clinical outcome measure of bronchodilator reversibility in COPD.
    Ben Saad H; Préfaut C; Tabka Z; Zbidi A; Hayot M
    Pulm Pharmacol Ther; 2008 Oct; 21(5):767-73. PubMed ID: 18555715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.